Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Spruce Biosciences presented long-term clinical data for its lead asset, tralesinidase alfa (TA-ERT), at the 18th International MPS Symposium. The data, covering 22 patients over six years, showed that TA-ERT stabilized cognitive, communication, and motor skills relative to the decline seen in untreated natural history patients.
Key figures
- Drug Name
- tralesinidase alfa
- Patient count
- 22
- Study duration years
- 6
- Total doses administered
- 6000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.